MAPT and Alzheimer disease: More recently, tau acetylation at other critical residues including K174, K274, and K281 has been shown to promote AD-related cognitive deficits, synaptic defects, and impaired hippocampal long-term potentiation (LTP) [6, 7], strongly implicating tau acetylation in AD pathogenesis.